Hashim PW, et al. - Researchers conducted this double-blind, randomized, vehicle-controlled trial to evaluate the safety and effectiveness of crisaborole 2% ointment, a nonsteroidal, phosphodiesterase-4 inhibitor, in the treatment of intertriginous, anogenital, and facial psoriasis. Participants in the study were 21 subjects. For this investigation, study participants were randomized 2:1 to receive 4 weeks of twice daily treatment with either crisaborole 2% ointment (n=14) or vehicle ointment (n=7), followed by 4 weeks of open label treatment with crisaborole 2% ointment. Subjects in the crisaborole group showed 66% improvement after 4 weeks vs 9% in the vehicle group. In subjects with intertriginous, anogenital, or facial psoriasis, treatment with crisaborole 2% ointment was well-tolerated and led to clinical improvement. No adverse events have occurred.